info@mail.ucallm.com
From Molecular Classification to Precision Hepatic Oncology — Empowering Reliable Liver Cancer Profiling with Validated Antibody Solutions
Liver cancer is among the leading causes of cancer-related mortality worldwide, with hepatocellular carcinoma (HCC) accounting for approximately 90% of primary liver malignancies. The disease is characterized by marked molecular heterogeneity, chronic inflammation-driven tumorigenesis, metabolic reprogramming, vascular invasion, and high recurrence rates following treatment. Although biomarkers such as AFP remain widely used, their limited sensitivity and specificity underscore the need for comprehensive molecular profiling to improve diagnosis, prognosis, and therapeutic stratification.
We support advanced liver cancer biomarker research by enabling comprehensive investigation of tumor heterogeneity, molecular evolution, cancer metabolism, immune regulation, epigenetic mechanisms, and spatial tumor biology. Validated biomarker solutions empower researchers to characterize molecular subclasses, investigate clonal evolution and metabolic reprogramming, dissect tumor–immune interactions, and uncover genomic and epigenetic mechanisms underlying tumor progression and therapeutic response. Combined with single-cell analysis, spatial profiling, multiplex imaging, and AI-assisted digital pathology, liver cancer biomarker profiling enables high-resolution characterization of tumor heterogeneity, cellular interactions, and clinically relevant molecular phenotypes. These integrated approaches accelerate discoveries in precision hepatology, biomarker-guided therapeutic development, immuno-oncology, tumor evolution, and next-generation precision medicine.
Liver Cancer Biomarker Antibody Portfolio
——Comprehensive Solutions for Tumor Classification, Prognostic Assessment and Precision Oncology Research
Accurate liver cancer characterization requires integrated evaluation of lineage-specific markers, oncogenic signaling pathways, metabolic regulators, angiogenic factors, immune biomarkers, and genomic alterations. Our comprehensive antibody portfolio supports every stage of liver cancer biomarker research.
Biomarker Category | Representative Markers | Research Applications | Biological Significance |
Hepatocyte Lineage & Diagnosis | HepPar-1, Arginase-1, Glypican-3 (GPC3), AFP, CK8/18 | Tumor classification, HCC diagnosis | Identify hepatocellular differentiation and tumor origin |
Prognostic & Metastasis Markers | EpCAM, CD44, Vimentin, E-Cadherin, L1CAM | Invasion, recurrence, survival studies | Reflect EMT, stemness and metastatic potential |
Cell Proliferation & Cell Cycle | Ki-67, Cyclin D1, PCNA | Tumor growth assessment | Evaluate proliferative activity |
Genomic Drivers & Tumor Suppressors | TP53, AXIN1, ARID1A, RB1 | Mutation-associated biology | Reveal molecular drivers of hepatocarcinogenesis |
Signal Transduction Markers | p-AKT, p-ERK1/2, mTOR, STAT3, YAP, CTNNB1 (β-Catenin) | Targeted therapy research | Characterize oncogenic signaling activation |
Angiogenesis & Hypoxia Markers | VEGFA, VEGFR2, HIF-1α, CD31 | Tumor vascular biology | Investigate angiogenesis and hypoxia |
Immune Microenvironment Markers | PD-L1, PD-1, CD8, FOXP3, CD68, CD163, Granzyme B | Immunotherapy biomarker studies | Characterize immune regulation |
Metabolic Biomarkers | GLUT1, LDHA, CPT1A, FASN | Cancer metabolism research | Evaluate metabolic reprogramming |
For Research Use Only. Not for use in diagnostic procedures
Key Liver Cancer Biomarker Targets
——Molecular Functions and Research Applications
Marker | Biological Function | Research Value | Associated Liver Cancer |
Glypican-3 (GPC3) | Cell surface heparan sulfate proteoglycan | HCC diagnosis and targeted therapy research | Hepatocellular carcinoma |
HepPar-1 | Hepatocyte differentiation marker | Tumor origin identification | Hepatocellular carcinoma |
Arginase-1 | Urea cycle enzyme | Highly specific hepatocyte marker | Hepatocellular carcinoma |
AFP | Oncofetal glycoprotein | Disease monitoring and biomarker studies | HCC |
EpCAM | Cancer stem cell marker | Stemness and recurrence studies | HCC |
CD44 | Cell adhesion receptor | Metastasis and therapy resistance | Advanced HCC |
Ki-67 | Cell proliferation marker | Tumor grading and prognosis | HCC |
β-Catenin | Wnt signaling regulator | Molecular subtype characterization | CTNNB1-mutated HCC |
TP53 | Tumor suppressor | Genomic instability studies | Aggressive HCC |
YAP | Hippo pathway effector | Tumor progression research | HCC |
VEGFA | Angiogenic growth factor | Anti-angiogenic therapy research | Advanced HCC |
HIF-1α | Hypoxia-responsive transcription factor | Tumor hypoxia studies | HCC |
PD-L1 | Immune checkpoint ligand | Immunotherapy biomarker | HCC |
CD8 | Cytotoxic T-cell marker | Immune infiltration analysis | HCC |
FASN | Lipid synthesis enzyme | Metabolic reprogramming | HCC |
GLUT1 | Glucose transporter | Warburg effect studies | HCC |
p-AKT | PI3K/AKT pathway activation | Targeted signaling analysis | HCC |
Featured Liver Cancer Research Panels
——Integrated Biomarker Solutions for Comprehensive Liver Cancer Characterization
HCC Diagnostic & Differentiation Panel—Establishing Hepatocellular Origin and Malignant Phenotype
Key Markers
HepPar-1 | Arginase-1 | GPC3 | AFP | CK8/18 | Ki-67 | CK19 |
EMT & Metastasis Panel—Investigating Epithelial-Mesenchymal Transition and Metastatic Dissemination
Key Markers
E-Cadherin | N-Cadherin | Vimentin | Snail | Slug | L1CAM |
Tumor Immunology Panel—Profiling the Immune Contexture and Immunotherapeutic Targets
PD-L1 | CD8 | CD68 | FOXP3 | Granzyme B | CD163 |
Cancer Metabolism Panel—Evaluating Metabolic Reprogramming in Hepatocarcinogenesis
GLUT1 | LDHA | PKM2 | FASN | CPT1A | AMPK |
Liver Cancer Biomarker Research
——From Molecular Profiling to Translational Discovery
Research Stage | Representative Markers | Scientific Objective |
Tumor Classification | HepPar-1, GPC3, Arginase-1 | Define liver tumor identity |
Cell Proliferation Analysis | Ki-67, Cyclin D1 | Evaluate tumor growth |
EMT & Metastasis | EpCAM, CD44, Vimentin | Investigate invasion mechanisms |
Signaling Pathway Research | AKT, ERK, mTOR, YAP | Study oncogenic signaling |
Immune Profiling | PD-L1, CD8, CD68 | Characterize tumor immunity |
Angiogenesis Research | VEGFA, CD31, HIF-1α | Analyze vascular remodeling |
Metabolic Reprogramming | GLUT1, LDHA, FASN | Investigate cancer metabolism |
Translational Biomarker Discovery | TP53, CTNNB1, GPC3 | Identify therapeutic biomarkers |
The Liver Cancer Biomarker Research Workflow integrates molecular profiling, tumor characterization, and translational biomarker discovery to advance precision hepatocellular carcinoma research. By analyzing key markers involved in tumor classification, proliferation, EMT and metastasis, oncogenic signaling, immune regulation, angiogenesis, and metabolic reprogramming, researchers can define tumor biology and identify mechanisms driving disease progression. Biomarkers such as HepPar-1, GPC3, Ki-67, EpCAM, YAP, PD-L1, VEGFA, GLUT1, TP53, and CTNNB1 support comprehensive evaluation of tumor identity, therapeutic response, and potential precision oncology strategies.
Why Researchers Choose Our Liver Cancer Biomarker Solutions?
Validated Targets. Comprehensive Panels. Reliable Translational Research.
Our antibody portfolio supports the complete liver cancer research workflow—from molecular classification and biomarker discovery to precision oncology and therapeutic development.
Research Challenge | Our Solution |
How can I classify liver cancer subtypes? | Comprehensive hepatocyte lineage markers including GPC3, HepPar-1, Arginase-1 and AFP |
How can I investigate tumor progression? | Biomarkers covering proliferation, EMT, angiogenesis and metastasis |
How can I study oncogenic signaling? | Antibodies targeting PI3K/AKT, MAPK, Wnt/β-catenin, Hippo and mTOR pathways |
How can I evaluate immunotherapy biomarkers? | Immune profiling panels including PD-L1, CD8, CD68 and FOXP3 |
How can I improve experimental reproducibility? | Highly validated recombinant antibodies optimized for IHC, WB, ICC/IF, multiplex IF and flow cytometry |
Key References
Llovet J.M., Kelley R.K., Villanueva A., et al. (2021). Hepatocellular carcinoma. Nature Reviews Disease Primers. 7:6.
Johnson P., Zhou Q., Dao D.Y., et al. (2022). Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma. Nature Reviews Gastroenterology & Hepatology. 19:670–681.
Greten T.F., Villanueva A., Korangy F., et al. (2023). Biomarkers for immunotherapy of hepatocellular carcinoma. Nature Reviews Clinical Oncology. 20:780–798.
Cheng M., Zheng X., Wei J., Liu M. (2023). Current state and challenges of emerging biomarkers for immunotherapy in hepatocellular carcinoma (Review). Experimental and Therapeutic Medicine. 26:586.
Feng N., Yu F., Yu F., et al. (2022). Metabolomic biomarkers for hepatocellular carcinoma: A systematic review. Medicine (Baltimore). 101:e28510.